Clinical Trial Update: Trial of Capecitabine With or Without Irinotecan Driven by UGT1A1 [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating capecitabine with or without irinotecan in locally advanced rectal cancer has been completed, with study driven by UGT1A1 status.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rectal Cancer

Drugs mentioned

• Capecitabine (capecitabine)
• Irinotecan (Irinotecan)

Snippet

Sponsor: Fudan University | Conditions: Locally Advanced Rectal Cancer | Phase 3 | Status: COMPLETED